Empagliflozin in Patients with Chronic Kidney Disease

🤖 Plain-English Summary

BACKGROUND: The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. CONCLUSIONS: Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo.

🔑 Key Findings

• The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients.
• METHODS: , a sustained decrease in eGFR of ≥40% from baseline, or death from renal causes) or death from cardiovascular causes.
• RESULTS: A total of 6609 patients underwent randomization.

🔗 Related Resources